TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06690892

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-to-eat beef in frozen, 5-oz packages
Description: The dietary intervention lasts 12 weeks for each individual. Participants in the experimental group will receive this intervention. Each participant will acquire 5 portions of ready-to eat beef in frozen packages per week (1 portion of sirloin cap steak strips, 1 portion of shredded chuck roast, 1 portion of petite shoulder medallions, and 2 portions of ground beef crumbles); each portion of ready-to-eat beef in this intervention will weigh 5 ounces.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ready-to-eat beef in frozen, 1-oz packages
Description: The dietary intervention lasts 12 weeks for each individual. Participants in the control group will receive this intervention. Each participant will acquire 5 portions of ready-to eat beef in frozen packages per week (1 portion of sirloin cap steak strips, 1 portion of shredded chuck roast, 1 portion of petite shoulder medallions, and 2 portions of ground beef crumbles); each portion of ready-to-eat beef in this intervention will weigh 1 ounces.
Study: NCT06689787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Guided STAIR Coach with Real-Time Assessment
Description: Two mobile apps to be used as one intervention package to support participants in their progress through STAIR (Skills Training in Affective and Interpersonal Regulation) with self-monitoring of symptoms and functioning

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Real-Time Assessment
Description: One mobile app to support participants in self-monitoring of symptoms and functioning
Study: NCT06690632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water preparation
Description: ingestion of 1.5L of water 30min prior MRE acquisition

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol preparation
Description: ingestion of 1.5L of water diluted PEG 45 min prior MRE acquisition (standard protocol)
Study: NCT06687005

Intervention type: PROCEDURE
Intervention: non-surgical periodontal therapy
Description: non-surgical periodontal therapy

Intervention type: PROCEDURE
Intervention: non-surgical periodontal therapy
Description: non-surgical periodontal therapy
Study: NCT06691633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preoperative Methadone
Description: patient receives a one-time preoperative dose of 10 mg of methadone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Oxycodone
Description: patient receives a one-time preoperative dose of 10 mg of oral oxycodone
Study: NCT06695884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized. Stimulation will be delivered to the L-DLPFC using a active/placebo figure-8 coil and a magventure TMS device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized. Stimulation will be delivered to the L-DLPFC using a active/placebo figure-8 coil and a magventure TMS device.
Study: NCT06687941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-201
Description: AST-201 is administered intravenously on Days 1, 8, and 15 of each 28-day cycle, followed by a one-week rest period. Dosing is repeated until DLT or disease progression is occurred.
Study: NCT06687161

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS) therapy
Description: Each treatment consists of 600 TMS pulses (\~3 minutes) applied to the L-DLPFC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation (TMS) therapy
Description: Each treatment consists of 600 TMS pulses (\~3 minutes) applied to the L-DLPFC

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy for insomnia (CBT-I)
Description: 9-week fully-automated, Internet-delivered CBT-I program: SHUTi OASIS (Sleep Healthy Using the Internet for Older Adult Sufferers of Insomnia and Sleeplessness)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy for insomnia (CBT-I)
Description: 9-week fully-automated, Internet-delivered CBT-I program: SHUTi OASIS (Sleep Healthy Using the Internet for Older Adult Sufferers of Insomnia and Sleeplessness)
Study: NCT06687707

Intervention type: OTHER
Intervention: Attitude Scale towards Physiotherapy Profession
Description: It is a questionnaire that evaluates the attitudes of physiotherapists with 35 questions under 3 headings: professional satisfaction, qualifications required by the profession, and concerns about the profession. It was developed in 2018 by Begümhan Turhan. In this scale, which is a Likert-type questionnaire, each question is scored between 0 and 5 points. The minimum score that can be obtained from the scale is 35 and the maximum score is 175. A high score indicates that physiotherapists have a positive attitude towards their profession

Intervention type: OTHER
Intervention: Minnesota Job Satisfaction Scale
Description: It is a 20-item Likert-type questionnaire. Scores less than 3 points indicate low job satisfaction. Turkish validity and reliability studies were conducted. The validity and reliability study in Turkey was conducted by Baycan and the Cronbach's alpha value of the scale was found to be 0.77. It is a tool consisting of 20 items with features that reveal internal and external job satisfaction factors. The neutral satisfaction score of the scale is 3. If the score obtained from the scale is less than 3, job satisfaction is considered low, and if it is greater than 3, job satisfaction is considered high.

Intervention type: OTHER
Intervention: Maslach Burnout Scale
Description: The Burnout Inventory, which was developed by Maslach and Jackson (1981) and introduced to the literature under Maslach's name, is a seven-point Likert-type scale and consists of a total of 22 items and three subscales. Among these subscales, emotional exhaustion subscale consists of 9 items, depersonalisation subscale consists of 5 items and personal accomplishment subscale consists of 8 items. Scale items are scored as '1 never' and '7 always'. The Turkish validity and reliability of the questionnaire was conducted by Burhan Çapri. It is a 5-point Likert-type scale measured with 0: never 4: always options. High scores are expected
Study: NCT06686446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Education Package
Description: Participants randomised to the intervention arm will receive an advanced patient education toolkit and reminders delivered by email/SMS in addition to the standard education provided by their treating clinician.~Weekly repeat reminders - these reminders will be sent via either SMS or email over a period of 3 months. They will instruct and remind the participant to take their INCS/INAH as per their treating clinician recommendation and why it is important to take it as instructed.~Education Toolkit - contains links to websites of key organisations including the National Allergy Council (NAC), Allergy \& Anaphylaxis Australia (A\&AA), Australasian Society of Clinical Immunology and Allergy (ASCIA), National Asthma Council Australia (NACA) and AusPollen which include educational videos and other resources.
Study: NCT06690788

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual intervention condition (PreventT2)
Description: PreventT2 will be delivered by a team of trained CDC National Diabetes Prevention Program (NDPP) Lifestyle Coaches to adults at high risk for diabetes. The 2021 version of the lifestyle intervention curriculum to be used is freely available from the CDC. The intervention will be delivered in the context of the University of Utah National DPP, which has Full recognition from the CDC based on outcome data over the course of a number of years.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple-based intervention condition (PreventT2 Together) (couple-based adaptation of 2021 PreventT2; approved by the CDC in November 2022 as an Alternate Curriculum for use in the NDPP
Description: PreventT2 Together will be delivered by a team of trained CDC National DPP Lifestyle Coaches to adults at high risk for diabetes and their partners. The lifestyle intervention curriculum was developed with the input of a community advisory board and was approved by the CDC for use in the National DPP (Diabetes Prevention Program) (i.e., meets CDC Diabetes Prevention Recognition Program Standards, including 22+ classes delivered over the course of 12 months and targeting lifestyle changes to prevent type 2 diabetes). In contrast to PreventT2, the intervention includes content specific to couples with prompts encouraging partners to consider and discuss how they can best support one another, information about lifestyle intervention in a relationship context, and examples demonstrating how couples collaborated to make healthy lifestyle changes.
Study: NCT06368193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuralert Monitor
Description: Device to identify upper extremity asymmetry in patients who are high risk for stroke.
Study: NCT06359626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHP2205
Description: Test drug: YHP2205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHP2205
Description: Test drug: YHP2205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR2401
Description: comparator: YHR2401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHR2401
Description: comparator: YHR2401
Study: NCT06694350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab+Flutamide
Description: Pembrolizumab 200mg ivgtt once +Flutamide 250mg，Q8h
Study: NCT05339659

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mHealth Intervention
Description: Mobile health (mHealth) app to motivate and support quitting smoking.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mHealth Intervention
Description: Mobile health (mHealth) app to motivate and support quitting smoking.
Study: NCT04950764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seladelpar 10 mg
Description: Seladelpar 10 mg single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seladelpar 10 mg or less
Description: Seladelpar 10 mg or less, once daily for 28 days
Study: NCT05272176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Long Term with Active Suicide Program (CLASP)
Description: Telehealth-based case management intervention designed to reduce suicidal behavior among individuals at high risk for suicide across the transition from inpatient hospitalization to the community.
Study: NCT05478213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monophasic Action Potential (MAP) Catheter
Description: The EasyMap catheter is a temporary quadripolar catheter for recording monophasic action potentials and for intracardiac pacing. During a standard of care VT ablation, the MAP catheter will be used to study cellular action potential of the ventricular myocardium, which cannot be done on traditional catheters. The catheter is placed on the myocardium (similar to other traditional catheters) and a recording signal is transmitted to the workstation. Using the MAP catheter the will not interrupt or distort any of the standard treatment procedures.
Study: NCT04619147

Intervention type: OTHER
Intervention: No intervention
Description: This is descriptive, retrospective study to evaluate the epidemiology of invasive fungal infections (IFI) in patients undergoing allogeneic haematopoiectic stem cell transplant in the era of antifungal prophylaxis with posaconazole delay-released tablets.

Intervention type: OTHER
Intervention: No intervention
Description: This is descriptive, retrospective study to evaluate the epidemiology of invasive fungal infections (IFI) in patients undergoing allogeneic haematopoiectic stem cell transplant in the era of antifungal prophylaxis with posaconazole delay-released tablets.
Study: NCT06542289

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BlinkER device.
Description: Participants will use the BlinkER System for 8-16 hours daily (removed during sleep) at approximately 10 blinks/minute. The stimulation cycle will be ON and OFF to achieve the desired blink rate. Participants will receive training on device usage before starting the study.
Study: NCT06055569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation protocol: AOT+NMES
Description: Action observation and neuromuscular electrical stimulation followed by motor execution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation protocol: Action Observation Therapy (AOT)
Description: Action observation followed by motor execution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Observation of motor-neutral stimuli (MNO)
Description: Motor-neutral observation followed by motor execution
Study: NCT05209295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onureg
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onureg
Description: Specified dose on specified days

Intervention type: DRUG
Group type: OTHER
Intervention: Onureg
Description: Specified dose on specified days
Study: NCT05893030

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anesthesia guided by sedation and analgesia monitoring
Description: Anesthesia guided by sedation and analgesia monitoring The level of sedation will be monitored by~* Monitoring System BIS™ : Bispectral index (BIS) between 45 and 60 AND Suppression Ratio (SR) at 0;~* or SedLine® Sedation Monitor : Patient State Index (PSi) between 25 and 50;~* or Entropy Sensor™: State entropy (SE) between 45 and 60 AND Burst Suppression Ratio (BSR) at 0;~and the level of nociception by :~* Nociception monitor PMD-200® : Nociception Level (NoL) between 10 and 25.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: anesthesia performed according only to the clinical judgment of the anesthetist as usual practice
Description: Administration of anesthesia will be performed according to the clinical judgment of the anesthetist as usual practice without sedation and analgesia monitoring
Study: NCT04818177

Intervention type: DRUG
Intervention: Institutional standard intravenous immune globulin treatment
Description: No treatments will be prospectively assigned. Subjects will receive their standard intravenous immune globulin doses. We will measure body composition and identify the relationship between body composition and intravenous immune globulin disposition.

Intervention type: DRUG
Intervention: Institutional standard intravenous immune globulin treatment
Description: No treatments will be prospectively assigned. Subjects will receive their standard intravenous immune globulin doses. We will measure body composition and identify the relationship between body composition and intravenous immune globulin disposition.
Study: NCT06421285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise, Strength training, Flexibility exercise
Description: Aerobic exercise: 30-40 minutes/time, 3-5 times a week, intensity of 4-6 points on the Rating of Perceived Exertion(RPE) 10-point scale(A simple conversation is possible during exercise, but the intensity is such that you feel out of breath) Strength training: 2-3 times a week, 3 sets of 10 repetitions per movement~* Upper extremities: Biceps brachii, triceps brachii, deltoid, pectoralis muscle exercise~* Lower extremities: gluteus maximus, hamstrings, quadriceps exercise Flexibility exercise: Stretching and mobility exercises reflecting post-surgery rehabilitation
Study: NCT06444737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron
Description: Intravenous (IV) ondansetron 0.10 mg/ kg diluted in 5 ml normal saline, 5 min before spinal anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous normal saline
Description: Intravenous normal saline 5 ml (control group) 5 min before spinal anesthesia
Study: NCT04744831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a 5.4 mg/kg Q3W
Description: DS-8201a for injection will be administered intravenously (IV) at a dose of 5.4 mg/kg every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-8201a 6.4 mg/kg Q3W
Description: DS-8201a for injection will be administered intravenously (IV) at a dose of 6.4 mg/kg every 3 weeks (Q3W)
Study: NCT06145711

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hiPSC-DAP
Description: Using hiPSC-DAP for the treatment of the patients of Parkinson's diease
Study: NCT05891782

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HAPA-based Multidomain Fall Risk Management
Description: According to the HAPA and the conceptual model of IC, this intervention consists of 3 stages.~Stage 1: The main format will be group lectures and scenario simulation, each intervention will have a duration of 30 to 45 minutes. Intervention content will utilize BCT \[5.1, 5.3, 5.5, 5.6, 9.3, 15.1\] .~Stage 2: This stage will utilize mostly group lectures or one-to-one interviews, to provide an action and coping plan to participants for fall risk management. This will apply BCT \[1.1-1.4, 4.1\] at week 4.Firstly, individualized targets will be established. Secondly, professionals and participants will collaborate to develop an implementation plan.~Stage 3:Recovery self-efficacy will be implemented as group discussions, with each intervention lasting 15-30 minutes. Maintenance will be implemented in one-to-one interviews, with each intervention lasting 15-30 minutes.Finally, the consolidation and outlook will provide the foundation for the habit formation of healthy behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular health education lectures
Description: Weeks 1-4 will be provided with fall-related regular health education lectures. Weeks 5-16 will have regular activities according to the daily arrangement of the nursing home. Meanwhile, telephone, WeChat, or face-to-face interviews will be conducted fortnightly, to understand the needs of the participants. During the process, staff will provide usual care such as vital signs monitoring, disease treatment, medication prescription, and health record maintenance.
Study: NCT06454487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric Hand Grip Training
Description: IHG training will be performed with an inflatable ball three days per week for 12 weeks (with at least a day of rest between each session) with intensity set based on RPE (Borg CR-10 scale).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CR
Description: Standard of Care
Study: NCT06197802

Intervention type: BIOLOGICAL
Intervention: Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)
Description: Three doses administered intramuscularly at 0, 45 day and 6 month.

Intervention type: BIOLOGICAL
Intervention: Gardasil®9
Description: Three doses administered intramuscularly at 0, 45 day and 6 month.
Study: NCT05535855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19 Directed CAR T Cell
Description: The UCD19 CAR T cells are developed through transfection of autologous peripheral blood mononuclear cells with a lentivirus carrying the DNA that encodes a short chain fragment variable region (scFv) derived from an anti-CD19 monoclonal antibody, among other elements.
Study: NCT05411120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Western Diet
Description: Western Diet is by high intakes of pre-packaged foods, refined grains, red meat, processed meat, high-sugar drinks, candy and sweets, fried foods, conventionally-raised animal products, butter and other high-fat dairy products, and low intakes of fruits, vegetables, whole grains.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Western Diet
Description: Western Diet is by high intakes of pre-packaged foods, refined grains, red meat, processed meat, high-sugar drinks, candy and sweets, fried foods, conventionally-raised animal products, butter and other high-fat dairy products, and low intakes of fruits, vegetables, whole grains.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CLEAN-MED
Description: Mediterranean like diet is a high consumption of vegetables, oil and moderate consumption of protein, with no processed foods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CLEAN-MED
Description: Mediterranean like diet is a high consumption of vegetables, oil and moderate consumption of protein, with no processed foods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CLEAN-MED
Description: Mediterranean like diet is a high consumption of vegetables, oil and moderate consumption of protein, with no processed foods.
Study: NCT05626777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-filled syringe, mepolizumab 100 mg/month
Description: Pre-filled syringe, mepolizumab, 100 mg/month, 6 first months of treatment administered by nurse, 6 last months of treatment administered by patient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auto-injector pen, mepolizumab 100 mg/month
Description: Auto-injector pen, mepolizumab, 100 mg/month 12 months of treatment administered by patient
Study: NCT05298046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: TAVO101
Description: TAVO101 single ascending dose IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: TAVO101
Description: TAVO101 single ascending dose IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: TAVO101
Description: TAVO101 single ascending dose IV infusion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Other: Placebo
Description: Placebo single ascending dose IV infusion.
Study: NCT04775524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storytelling Through Music (STM)
Description: 6 week expressive arts-based program
Study: NCT05621460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 500mL carbonated water
Description: Drink 500mL carbonated water immediately prior to head-up tilt test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 500mL carbonated water
Description: Drink 500mL carbonated water immediately prior to head-up tilt test
Study: NCT04775524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wait List / Storytelling Through Music-Hybrid
Description: 2 week song listening program
Study: NCT04654052

Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel
Description: Clopidogrel during 11 months

Intervention type: DRUG
Group type: OTHER
Intervention: Previous treatment
Description: non-intervention